CClinicalTrials.gg
CompletedNCT03628989Updated Sep 28, 2023

Technology-Based Distractions During Minor Procedures

An interventional study of Use of Virtual Technology in Pain, Anxiety and Procedural Anxiety, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged Up to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
Up to 17 Years
Sex
All
01

Study summary

The purpose of this study is to determine if non-invasive distracting devices (Virtual Reality headset, Augmented Reality Headset) are more effective than the standard of care (i.e., no technology-based distraction) for decreasing anxiety and pain scores in pediatric patients undergoing various minor procedures (i.e lumbar punctures and cardiac catheterization). The anticipated primary outcome will be a reduction of overall cumulative medication and secondary outcomes include but are not limited to: physician satisfaction, discharge time, pain scores, anxiety scores, and procedure time.

02

Conditions studied

  • Pain
  • Anxiety
  • Procedural Anxiety

Browse trials for

03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 58 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 17 and under
  • Able to consent or have parental consent
  • Undergoing minor procedures (i.e lumbar punctures, cardiac catheterization) at Lucile Packard Children's Hospital (LPCH) or Stanford Hospital facilities

Exclusion criteria

Exclusion Criteria:

  • People who do not consent
  • Significant Cognitive Impairment
  • History of Severe Motion Sickness
  • Current Nausea
  • Seizures
  • Visual Problems
  • Non-English Speaking
  • Patients who clinically unstable or requires urgent/emergent intervention
  • (ASA) Physical status classification class 4 or higher
  • Patient or parental preference for General Anesthesia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    Cardiac Cathertization Patients

    Participants will use technology based distraction during procedure.

    Behavioral: Use of Virtual Technology

  • Experimental
    Allergy Patients

    Participants will use technology based distraction during procedure

    Behavioral: Use of Virtual Technology

  • No intervention
    Procedure-Only Patients

Interventions

  • BehavioralUse of Virtual Technology

    If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.

06

What researchers measure

Primary outcomes

  1. Measure anxiety score

    Numerical anxiety scale (0-10), 0 being no anxiety and 10 being the worst imaginable anxiety

    Time frame: Duration of procedure (usually no more than 2-4 hours)

Secondary outcomes

  1. Parent and Child Satisfaction Questionnaire

    Parent and child questionnaire with 5 questions asking the individual on a scale from 1-5 how much they agree with each statement (1=Not at all, 3=A little bit, 5=A lot). It has stamens such as "Having the technology made me feel more relaxed before my procedure" or "If I ever have procedure again, I would like to use this technology"

    Time frame: Duration of procedure (usually no more than 2-4 hours)

  2. Virtual and Augmented Reality Feedback Survey

    Measure satisfaction and feedback for Virtual Reality/ Augmented Reality in regards to software and hardware for future iterations.

    Time frame: Duration of procedure (usually no more than 2-4 hours)

  3. Asses cumulative medication dosing and the duration of procedure

    Measure dosing requirements for anxiolytic and/or analgesic medications for participants thought their procedure. We will then compare these doses to their own historical chart data, since many of these patents come in routinely, and use their own data for intra-reliability measures.

    Time frame: Duration of procedure (usually no more than 2-4 hours)

  4. Evaluation of Passive vs Active Interventions

    There is variation in the immersive technology experiences (active vs passive content), as a part of the study the investigators also aim to evaluate the degree of cognitive load which is suitable for clinical applications during minor procedures. During the participants immersive experience in either AR or VR, there are embedded questions in the experience that can gage as to the patient's emotional status (happy, sad, mad) or VAS scales (0-10, 0=no pain, 10=worst imaginable pain) that can let the research personnel know if we need to increase the cognitive load. If patients are self-reporting higher VAS scores, or aversive emotional status (i.e mad) the cognitive load will be increased to enhance the distraction experience from the procedure.

    Time frame: Duration of procedure (usually no more than 2-4 hours)

Other outcomes

  1. Fear assessment

    Patient's fear will be assessed through the Children's Fear Scale (CFS). Patients will be shown faces showing different levels of anxiety on a scale from 0 to 4. The left-most face (minimum value of 0) shows no anxiety at all and the right-most face shows extreme anxiety (maximum value of 4). Patients look at these faces and choose the one that shows how much anxiety was felt during procedure. This will be done only for allergy patients.

    Time frame: Duration of procedure (usually no more than 2-4 hours)

  2. Pain Assessment

    Patient's pain will be assessed through the Wong-Baker FACES pain rating scale from 0 to 10. The left-most face has a value of 0 meaning no pain/doesn't hurt at all and the right-most face has a value of 10 being a lot of pain/hurts as much as you can imagine. Patients will be asked which face best describes their pain levels during the procedure. This will only be done for allergy patients.

    Time frame: Duration of procedure (usually no more than 2-4 hours)

  3. Procedural Compliance

    Procedural compliance is measured through modified Induction Compliance Checklist (ICC). All behaviors observed in checklist are marked. Total score is the number of categories checked, perfect score is 0. This will only be done for allergy patients.

    Time frame: Duration of procedure (usually no more than 2-4 hours)

07

Study locations

1 site
  • Lucile Packard Children's Hospital Stanford
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03628989
Lead sponsor
Stanford University
Responsible party
Samuel Rodriguez (Professor, Stanford University) — Principal investigator
First posted
Aug 14, 2018
Start date
Jun 1, 2018
Primary completion
Jun 30, 2023
Completion
Jul 11, 2023
Last update
Sep 28, 2023

Study contacts

Thomas J Caruso, MD, MEd
principal investigator · Stanford University
Samuel Rodriguez, MD
principal investigator · Stanford University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion